[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621792":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":10,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Federico II University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Subjects with hyperlipidaemia under Alirocumab 300 mg treatment.",null,"Subjects with hyperlipidaemia",[13],"Drug: Praluent (Alirocumab)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Praluent (Alirocumab)","Alirocumab 300 mg injection",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Pasquale Perrone Filardi","CONTACT","+390817462224","fpperron@unina.it",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Federico II University of Naples, Department of Advanced Biomedical Sciences","RECRUITING","Naples","Napoli","80131","Italy",{"type":35,"coordinates":36},"Point",[37,38],14.26811,40.85216,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":43,"investigatorFullName":22,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Professor","100621792",false,"NCT07375225","Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy","Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry","ALINET","Inclusion Criteria:\n\n\\- Patients under alirocumab 300mg treatment.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years o \\> 80 years;\n* Patients who refuse to participate and to sign informed consent.","ALL","18 Years","80 Years",{"count":56,"type":57},1500,"ESTIMATED","3 Years","OBSERVATIONAL","Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.",[62],"Hypercholesterolaemia","2026-01-21",{"date":65,"type":66},"2026-01-29","ACTUAL",{"date":68,"type":66},"2024-12-01",{"date":70,"type":57},"2027-12-01",{"name":5,"class":6},1]